Previous reports show that pyridostigmine interferes positively with several intracellular pathways; i.e., Lu et al. [18] demonstrated that pyridostigmine administration lowers the activation of the TGFβ1/TAK1 pathway, which is directly involved in cardiac hypertrophy and fibrosis. Here, TGFB1 is linked to cardiac hypertrophy.